Related Experiment Video
Updated: Jun 27, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
Optimization of rabies virus production in neuroblastoma cells using quality by design principles for vaccine and
Nayara Ugeda1, Orlando Garcia Ribeiro2, Elaine Raniero Fernandes1
1Rabies Diagnostic Laboratory, Pasteur Institute, São Paulo, SP, Brazil.
Abstract:
Efficient production of high-titer rabies virus (RABV) stocks is critical for vaccine development, diagnostic assay design, and virological research. This study employed a Quality by Design (QbD) framework to optimize RABV propagation in Neuro-2a (N2a) cells, targeting infectious titers ≥ 8.0 log₁₀ FFU/mL and cell viability ≥ 85 %. Three genetically distinct RABV strains were evaluated: the laboratory-adapted CVS-11 strain for vaccine production and two field isolates, MN-18 and V-M, relevant to diagnostics and research. A 2 ³ full factorial Design of Experiments (DOE) was implemented to assess the impact of multiplicity of infection (MOI), incubation temperature, and culture medium composition on critical quality attributes (CQAs). Distinct strain-specific responses were observed: CVS-11 and V-M were significantly influenced by MOI (p < 0.05), whereas MN-18 demonstrated a more stable replication profile. Enriched medium significantly enhanced viral titers and cell viability across all strains (p < 0.001). Monte Carlo simulations (n = 10,000) delineated an optimal operational space-MOI 0.1-1.0, temperature 34-35°C, enriched medium-ensuring process robustness with 95 % confidence. This QbD-guided strategy provides a scalable, reproducible platform for generating high-quality RABV stocks, facilitating the manufacture of CVS-11-based vaccines and supporting the diagnostic use of field isolates as biologically standardized reference reagents for diagnostics.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Vaccine Production
Vaccines
Rabies

